Artivion Inc (AORT)vsStryker Corporation (SYK)
AORT
Artivion Inc
$20.12
-3.45%
HEALTHCARE · Cap: $971.11M
SYK
Stryker Corporation
$305.66
+2.21%
HEALTHCARE · Cap: $119.69B
Smart Verdict
WallStSmart Research — data-driven comparison
Stryker Corporation generates 5409% more annual revenue ($25.27B vs $458.69M). SYK leads profitability with a 13.2% profit margin vs 2.5%. SYK appears more attractively valued with a PEG of 1.47. SYK earns a higher WallStSmart Score of 57/100 (C).
AORT
Hold41
out of 100
Grade: D
SYK
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-31.9%
Fair Value
$30.41
Current Price
$20.12
$10.29 premium
Margin of Safety
-39.3%
Fair Value
$223.02
Current Price
$305.66
$82.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
17.5% revenue growth
Large-cap with strong market position
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 2.6% — below average capital efficiency
2.5% margin — thin
Premium valuation, high expectations priced in
2.6% revenue growth
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AORT
The strongest argument for AORT centers on Price/Book, Revenue Growth. Revenue growth of 17.5% demonstrates continued momentum.
Bull Case : SYK
The strongest argument for SYK centers on Market Cap. PEG of 1.47 suggests the stock is reasonably priced for its growth.
Bear Case : AORT
The primary concerns for AORT are EPS Growth, Market Cap, Return on Equity. A P/E of 80.0x leaves little room for execution misses. Thin 2.5% margins leave little buffer for downturns.
Bear Case : SYK
The primary concerns for SYK are P/E Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
AORT profiles as a growth stock while SYK is a value play — different risk/reward profiles.
AORT carries more volatility with a beta of 1.26 — expect wider price swings.
AORT is growing revenue faster at 17.5% — sustainability is the question.
SYK generates stronger free cash flow (415M), providing more financial flexibility.
Bottom Line
SYK scores higher overall (57/100 vs 41/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Artivion Inc
HEALTHCARE · MEDICAL DEVICES · USA
Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.
Stryker Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?